What Are Eating Disorders?

Take our Disordered Eating Test

Find a therapist to heal from an eating disorder

GLP-1 drugs may benefit some people with binge eating disorder, but evidence remains limited.

GLP-1 drugs may trigger restrictive eating or relapse in vulnerable individuals.

Screening for eating disorders before prescribing GLP-1 drugs is essential.

Weight loss does not equal eating disorder recovery; ongoing monitoring is crucial.

GLP-1 medications, such as semaglutide and tirzepatide, have revolutionized the treatment of Type 2 diabetes and obesity. By reducing appetite, slowing gastric emptying, and promoting significant weight loss, they have generated considerable interest in both the medical field and public opinion.

However, their wider use in the population has raised an important question: What happens when these drugs are prescribed to people with eating disorders or who are at risk of developing them?

A recent consensus article published in World Psychiatry has addressed this question. Using the Delphi method, 45 experts and people with personal experience of eating disorders have elaborated several recommendations for clinical practice and future research.

The principal message of the consensus is that GLP-1 medications can offer several benefits, but they carry potential risks for people with eating disorders. Their use, therefore, requires careful attention, personalized decisions, and continuous monitoring.

Potential Benefits of GLP-1s for Binge Eating Disorder

There is growing interest in the possible use of GLP-1 medications in the treatment of binge-eating disorder (BED). Some studies have found a reduction in binge-eating episodes; however, the evidence remains limited because most studies are small, uncontrolled, retrospective, or based on single clinical cases.

Moreover, the study with the strongest methodological design found no significant reduction in binge-eating episodes with liraglutide compared with........

© Psychology Today